Medtronic CEO takes the helm amid investor speculation:
This article was originally published in Clinica
Medtronic's president and COO, William Hawkins, today succeeds Arthur Collins as the company's CEO. Mr Hawkins takes the helm amid speculation over whether he can increase the company's stock price and build up investor confidence (see Clinica No 1247, p 7). Missed earnings estimates is among the problems faced by the company. On August 21, the company's shares ended down 2% in after-hours trading following the announcement of weaker than expected first quarter sales in the company's implantable heart-regulating devices. Other problems include delays in getting new products to market and the lengthy transformation of insulin pump company MiniMed into a strong performing subsidiary. If Mr Hawkins cannot address these problems, some analysts believe that Medtronic will risk becoming an acquisition target. In-depth analysis to follow.
You may also be interested in...
A randomized COVID-19 study spanning the whole of the UK could help to bolster the UK’s reputation as a location for future clinical trials. It is also being seen partly as the result of the UK regulator's "decisive action" in fast-tracking trials for potential COVID-19 therapies.
Manufacturers of endoscopic equipment, biofeedback devices and thermometers were among those cited for regulatory violations in US FDA warning letters this week. A total of four device-related enforcement missives were released by the agency.
The biopharma industry has struggled to recruit patients into clinical trials that adequately reflect the diverse patient populations they hope to reach with new products. Failure to improve minority subgroup participation now will cost trial sponsors later.